Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics

Proteomics

Volumn 15, Issue 2-3, 2015, Pages 340-355

  Zhang, Xu ^a   Belkina, Natalya ^a   Jacob, Harrys Kishore Charles ^b,c,d   Maity, Tapan ^a   Biswas, Romi ^a   Venugopalan, Abhilash ^a   Shaw, Patrick G ^c   Kim, Min Sik ^c   Chaerkady, Raghothama ^c   Pandey, Akhilesh ^c,e   Guha, Udayan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Institute of Bioinformatics International Tech Park ^*  (India)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MANIPAL UNIVERSITY   (India)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Autophagy; EGFR; Erlotinib; Mass spectrometry; NSCLC; Phosphoproteomics; SILAC

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CASEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; INSULIN RECEPTOR; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; S6 KINASE; SCATTER FACTOR; STAT PROTEIN; PHOSPHOPEPTIDE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; AUTOPHAGY; CONTROLLED STUDY; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; HUMAN; LUNG; LUNG NEOPLASMS; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; POINT MUTATION; TUMOR CELL LINE;

ADENOCARCINOMA; AUTOPHAGY; CELL LINE, TUMOR; HUMANS; LUNG; LUNG NEOPLASMS; MASS SPECTROMETRY; PHOSPHOPEPTIDES; PHOSPHORYLATION; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTEOMICS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84921262801     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400315     Document Type: Article

References (58)

1. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11-30.
2. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S. et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
3. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S. et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
4. Pao, W., Miller, V., Zakowski, M., Doherty, J. et al., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 2004, 101, 13306-13311.
5. Pao, W., Miller, V. A., Politi, K. A., Riely, G. J. et al., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2, e73.
6. Kobayashi, S., Boggon, T. J., Dayaram, T., Janne, P. A. et al., EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352, 786-792.
7. Oxnard, G. R., Arcila, M. E., Sima, C. S., Riely, G. J. et al., Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin. Cancer Res. 2011, 17, 1616-1622.
8. Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E. et al., Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 2006, 116, 2695-2706.
9. Sordella, R., Bell, D. W., Haber, D. A., Settleman, J., Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305, 1163-1167.
10. Sharma, S. V., Gajowniczek, P., Way, I. P., Lee, D. Y. et al., A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006, 10, 425-435.
11. Sharma, S. V., Fischbach, M. A., Haber, D. A., Settleman, J., "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin. Cancer Res. 2006, 12, 4392s-4395s.
12. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B. et al., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 2002, 1, 376-386.
13. Blagoev, B., Kratchmarova, I., Ong, S. E., Nielsen, M. et al., A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling. Nat. Biotechnol. 2003, 21, 315-318.
14. Zhang, Y., Wolf-Yadlin, A., Ross, P. L., Pappin, D. J. et al., Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol. Cell. Proteomics 2005, 4, 1240-1250.
15. Olsen, J. V., Blagoev, B., Gnad, F., Macek, B. et al., Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006, 127, 635-648.
16. Tong, J., Taylor, P., Moran, M. F., Proteomic analysis of the epidermal growth factor receptor (EGFR) interactome and post-translational modifications associated with receptor endocytosis in response to EGF and stress. Mol. Cell. Proteomics 2014, 13, 1644-1658.
17. Rikova, K., Guo, A., Zeng, Q., Possemato, A. et al., Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131, 1190-1203.
18. Guo, A., Villen, J., Kornhauser, J., Lee, K. A. et al., Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. USA 2008, 105, 692-697.
19. Assiddiq, B. F., Tan, K. Y., Toy, W., Chan, S. P. et al., EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth. J. Proteome Res. 2012, 11, 4110-4119.
20. Kim, Y., Li, Z., Apetri, M., Luo, B. et al., Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib. Biochemistry 2012, 51, 5212-5222.
21. Zhang, G., Fang, B., Liu, R. Z., Lin, H. et al., Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. J. Proteome Res. 2011, 10, 305-319.
22. Guha, U., Chaerkady, R., Marimuthu, A., Patterson, A. S. et al., Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc. Natl. Acad. Sci. USA 2008, 105, 14112-14117.
23. Harsha, H. C., Molina, H., Pandey, A., Quantitative proteomics using stable isotope labeling with amino acids in cell culture. Nat. Protoc. 2008, 3, 505-516.
24. Zhong, J., Kim, M. S., Chaerkady, R., Wu, X. et al., TSLP signaling network revealed by SILAC-based phosphoproteomics. Mol. Cell. Proteomics 2012, 11, M112 017764.
25. Taouatas, N., Altelaar, A. F., Drugan, M. M., Helbig, A. O. et al., Strong cation exchange-based fractionation of Lys-N-generated peptides facilitates the targeted analysis of post-translational modifications. Mol. Cell. Proteomics 2009, 8, 190-200.
26. Pinkse, M. W., Lemeer, S., Heck, A. J., A protocol on the use of titanium dioxide chromatography for phosphoproteomics. Methods Mol. Biol. 2011, 753, 215-228.
27. Larsen, M. R., Thingholm, T. E., Jensen, O. N., Roepstorff, P., Jorgensen, T. J., Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol. Cell. Proteomics 2005, 4, 873-886.
28. Thingholm, T. E., Jorgensen, T. J., Jensen, O. N., Larsen, M. R., Highly selective enrichment of phosphorylated peptides using titanium dioxide. Nat. Protoc. 2006, 1, 1929-1935.
29. Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A. et al., Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 2011, 10, 1794-1805.
30. Hornbeck, P. V., Kornhauser, J. M., Tkachev, S., Zhang, B. et al., PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 2012, 40, D261-D270.
31. Xue, Y., Ren, J., Gao, X., Jin, C. et al., GPS 2.0, a tool to predict kinase-specific phosphorylation sites in hierarchy. Mol. Cell. Proteomics 2008, 7, 1598-1608.
32. Manning, B. D., Cantley, L. C., Hitting the target: emerging technologies in the search for kinase substrates. Sci. STKE 2002, 2002, PE49.
33. Chartier, M., Chenard, T., Barker, J., Najmanovich, R., Kinome Render: a stand-alone and web-accessible tool to annotate the human protein kinome tree. PeerJ 2013, 1, e126.
34. Tracy, S., Mukohara, T., Hansen, M., Meyerson, M. et al., Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 2004, 64, 7241-7244.
35. He, Z., Yang, C., Guo, G., Li, N., Yu, W., Motif-All: discovering all phosphorylation motifs. BMC Bioinformatics 2011, 12(Suppl 1), S22.
36. Obata, T., Yaffe, M. B., Leparc, G. G., Piro, E. T. et al., Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J. Biol. Chem. 2000, 275, 36108-36115.
37. Nigg, E. A., Targets of cyclin-dependent protein kinases. Curr. Opin. Cell Biol. 1993, 5, 187-193.
38. Kumar, N., Afeyan, R., Sheppard, S., Harms, B., Lauffenburger, D. A., Quantitative analysis of Akt phosphorylation and activity in response to EGF and insulin treatment. Biochem. Biophys. Res. Commun. 2007, 354, 14-20.
39. Sarbassov, D. D., Guertin, D. A., Ali, S. M., Sabatini, D. M., Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307, 1098-1101.
40. Guertin, D. A., Sabatini, D. M., Defining the role of mTOR in cancer. Cancer Cell 2007, 12, 9-22.
41. Gingras, A. C., Gygi, S. P., Raught, B., Polakiewicz, R. D. et al., Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 1999, 13, 1422-1437.
42. Gingras, A. C., Raught, B., Gygi, S. P., Niedzwiecka, A. et al., Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 2001, 15, 2852-2864.
43. Sonenberg, N., Hinnebusch, A. G., Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009, 136, 731-745.
44. Ruvinsky, I., Meyuhas, O., Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem. Sci. 2006, 31, 342-348.
45. Clark, A. S., West, K. A., Blumberg, P. M., Dennis, P. A., Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res. 2003, 63, 780-786.
46. Kim, Y. Y., Von Weymarn, L., Larsson, O., Fan, D. et al., Eukaryotic initiation factor 4E binding protein family of proteins: sentinels at a translational control checkpoint in lung tumor defense. Cancer Res. 2009, 69, 8455-8462.
47. Behrends, C., Sowa, M. E., Gygi, S. P., Harper, J. W., Network organization of the human autophagy system. Nature 2010, 466, 68-76.
48. Kirkin, V., McEwan, D. G., Novak, I., Dikic, I., A role for ubiquitin in selective autophagy. Mol. Cell 2009, 34, 259-269.
49. Yoshida, T., Zhang, G., Smith, M. A., Lopez, A. S. et al., Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Clin. Cancer Res. 2014, 20, 4059-4074.
50. Lee, B. Y., Hochgrafe, F., Lin, H. M., Castillo, L. et al., Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer. Mol. Cancer Ther. 2014, 13, 190-201.
51. Weber, C., Schreiber, T. B., Daub, H., Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J. Proteomics 2012, 75, 1343-1356.
52. Courcelles, M., Fremin, C., Voisin, L., Lemieux, S. et al., Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions. Mol. Syst. Biol. 2013, 9, 669.
53. Amin, N. D., Zheng, Y. L., Kesavapany, S., Kanungo, J. et al., Cyclin-dependent kinase 5 phosphorylation of human septin SEPT5 (hCDCrel-1) modulates exocytosis. J. Neurosci. 2008, 28, 3631-3643.
54. Blethrow, J. D., Glavy, J. S., Morgan, D. O., Shokat, K. M., Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates. Proc. Natl. Acad. Sci. USA 2008, 105, 1442-1447.
55. Kipreos, E. T., Wang, J. Y., Differential phosphorylation of c-Abl in cell cycle determined by cdc2 kinase and phosphatase activity. Science 1990, 248, 217-220.
56. Goedert, M., Jakes, R., Qi, Z., Wang, J. H., Cohen, P., Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. J. Neurochem. 1995, 65, 2804-2807.
57. Ahn, J. H., McAvoy, T., Rakhilin, S. V., Nishi, A. et al., Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56delta subunit. Proc. Natl. Acad. Sci. USA 2007, 104, 2979-2984.
58. Vizcaíno, J. A., Côté, R. G., Csordas, A., Dianes, J. A. et al., The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res 2012, 104, doi: 10.1093/nar/gks1262.